Replies to post #122623 on Biotech Values

[pcrutch]

FWIW, Oppenheimer analyst Bret Holley said $ARIA will price CML drug ponatinib aggressively - near Tasigna/Sprycel

It would be good to hear about the Rida NDA sooner than later. I also think they might to consider raising some capital here ( but maybe they're holding out to partner ex-US rights to Ponatinib?)

[biomaven0]

To what do you attribute the almost frenzied (but orderly) buying?

I have no idea what makes people decide to buy or sell most stocks. But here I would guess at some combination of institutional buying and the retail/momo crowd.

There aren't many biotechs that have the potential for three significant drugs, two of which are wholly owned.

Peter

[Double_Bagel]

To what do you attribute the almost frenzied (but orderly) buying? Since investor day the volume has been very heavy. It is far and away my biggest holding, and I too am tempted at times to sell some.

I subscribe to Hilary Kramer's game changer stocks. She has been pushing ARIA for the last month or so. She is urging her subscribers to buy ARIA any time it dips below $11 (she raised it from $9) and to hold till it reaches $15. I haven't bought yet.
My profits from other stocks are going into MNTA right now :-)